ELTP (Elite Pharmaceuticals) Interest Expense: $-0.5 Mil (TTM As of Dec. 2025)


ELTP Elite Pharmaceuticals Inc ELTP
44 GF Score
Price $0.40
GF Value $0.57
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Elite Pharmaceuticals Interest Expense?

Elite Pharmaceuticals ELTP +2.62% 44 Interest Expense is $-0.5 Mil as of Dec. 2025. GuruFocus rates ELTP with a GF Score™ of 44/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Elite Pharmaceuticals's interest expense for the three months ended in Dec. 2025 was $ -0.1 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.5 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Elite Pharmaceuticals's Operating Income for the three months ended in Dec. 2025 was $ 9.0 Mil. Elite Pharmaceuticals's Interest Expense for the three months ended in Dec. 2025 was $ -0.1 Mil. Elite Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2025 was 112.66. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Elite Pharmaceuticals  (OTCPK:ELTP) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Elite Pharmaceuticals's Interest Expense for the three months ended in Dec. 2025 was $-0.1 Mil. Its Operating Income for the three months ended in Dec. 2025 was $9.0 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2025 was $4.9 Mil.

Elite Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Interest Coverage=-1* Operating Income (Q: Dec. 2025 )/Interest Expense (Q: Dec. 2025 )
=-1*9.013/-0.08
=112.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Elite Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

Elite Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for Elite Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elite Pharmaceuticals Interest Expense Chart

Elite Pharmaceuticals Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.26 -0.19 -1.11 -0.59 -0.77

Elite Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.19 -0.16 -0.08 -0.08
ELTP
44GF Score
Elite Pharmaceuticals Inc ELTP
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elite Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-0.5 Mil mean?
Elite Pharmaceuticals (ELTP) has a Interest Expense of $-0.5 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Elite Pharmaceuticals and its competitors.
Is Elite Pharmaceuticals' Interest Expense too high?
Elite Pharmaceuticals' current Interest Expense is $-0.5 Mil. Overall, Elite Pharmaceuticals has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' Interest Expense compare to EBS and NIKA?
Elite Pharmaceuticals' Interest Expense of $-0.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Elite Pharmaceuticals and its competitors. Elite Pharmaceuticals's current Interest Expense is $-0.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.40 — trading 30.7% below its estimated fair value. The current Interest Expense is $-0.5 Mil. Elite Pharmaceuticals' overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current Interest Expense is $-0.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?

Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued. The current stock price of $0.40 is trading 30.7% below its estimated GF Value™ of $0.57. GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.

Key valuation signals for ELTP:

  • Interest Expense: $-0.5 Mil
  • GF Value™: $0.57 vs. price of $0.40 (30.7% below fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elite Pharmaceuticals Business Description

Address 165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
44GF Score

Get the complete analysis for ELTP

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.40
Price
$0.57
GF Value